First-in-human (FIH) trial evaluating immune activation and safety of PIN-2 administered intravenously to patients with advanced solid tumors.

被引：0
|
作者：
Bier, Colin
Millward, Michael
Kotasek, Dusan
Gorelick, Kenneth J.
Goldberg, Joshua Brian
机构：
[1] PIN Pharma Inc, New York, NY USA
[2] Sch Med & Pharmacol, Nedlands, WA, Australia
[3] Adelaide Canc Ctr, Kurralta Pk, Adelaide, SA, Australia
[4] Univ Adelaide, Kurralta Pk, Adelaide, SA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2600
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-human trial of ONC201 in patients with refractory solid tumors.
    Stein, Mark N.
    Chan, Nancy
    Silk, Ann W.
    Fang, Bruno
    Kaufman, Howard
    Haffty, Bruce George
    Saunders, Tracie
    Najmi, Saltanat
    Zheng, Ling
    Stogniew, Martin
    Allen, Joshua E.
    Oster, Wolfgang
    Bertino, Joseph R.
    Mehnert, Janice M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] First-in-human study of PM14 in patients with advanced solid tumors.
    Vieito, Maria
    Aix, Santiago Ponce
    Paz-Ares, Luis G.
    Bahleda, Rastilav
    Massard, Christophe
    Agreda, Leyre
    Banus, Eva
    Fernandez, Cristian Marcelo
    Cristoveanu, Elena Y.
    Corral, Gema
    Llanero, Lourdes
    Lubomirov, Rubin
    Kahatt, Carmen Maria
    Fudio, Salvador
    Nieto, Antonio
    Cullell-Young, Martin
    Zeaiter, Ali Hassan
    Oberoi, Honey Kumar
    Garralda, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Chen, Yu-ling
    Jia, Ru
    Shen, Lin
    Wang, Jian
    Sai, Yang
    Qi, Chuan
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Doroshow, Deborah Blythe
    Seiwert, Tanguy Y.
    Gibson, Michael K.
    Velcheti, Vamsidhar
    Lisberg, Aaron Elliott
    Patel, Shetal Arvind
    Scheffler, Matthias
    Lafleur, Francois
    Dugan, Margaret Han
    Sharma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.
    Perets, Ruth
    Geva, Ravit
    McKean, Meredith
    Goutopoulos, Andreas
    Erez, Omri
    Phadnis, Monica
    Youssoufian, Hagop
    Schwartz, Brian E.
    Kansra, Vikram
    Fattaey, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
    De Bono, Johann Sebastian
    Mina, Lida A.
    Gonzalez, Michael
    Curtin, Nicola J.
    Wang, Evelyn
    Henshaw, Joshua W.
    Chadha, Manpreet
    Sachdev, Jasgit C.
    Matei, Daniela
    Jameson, Gayle S.
    Ong, Michael
    Basu, Bristi
    Wainberg, Zev A.
    Byers, Lauren Averett
    Chugh, Rashmi
    Dorr, Andrew
    Kaye, Stanley B.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.
    Hong, David S.
    Garrido-Laguna, Ignacio
    Krop, Ian E.
    Subbiah, Vivek
    Werner, Theresa Louise
    Cotter, Christine M.
    Hamilton, Erika Paige
    Velastegui, Karen
    Xuan, Dawei
    Bugarini, Roberto
    Gollerkeri, Ashwin
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors.
    Sarantopoulos, John
    Mahalingam, Devalingam
    Sharma, Neelesh
    Iyer, Renuka, V
    Wee, Wen
    Ahluwalia, Manmeet Singh
    Johnson, Saramarie
    Purmal, Andrei
    Shpigotskaya, Polina
    Hards, Ann
    Leonov, Andrey
    Gurova, Katerina
    Gudkov, Andrei
    Zakurdaeva, Kristina
    Miller, Langdon L.
    Dowlati, Afshin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] First-in-human trial of 4′-thio-2′-deoxycytidine (TdCyd) in patients with advanced solid tumors
    Coyne, G. O'Sullivan
    Chen, A.
    Kummar, S.
    Collins, J. M.
    Meehan, R. S.
    Suto, M.
    Rubinstein, L.
    Kinders, R.
    Moore, N.
    Parchment, R.
    Horneffer, Y.
    Juwara, L.
    Difilippantonio, M.
    Piekarz, R.
    Doroshow, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345